FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:06:081 | Safety of JAK inhibitors compared to non-TNF-targeted biologic therapies in rheumatoid arthritis patients who are inadequate responders to TNF inhibitors Lorenzo Di Luozzo1, Alessandro Giollo1, Mariangela Salvato1, Francesca Frizzera1, Kiren Khalid1, Margherita Zen1, Andrea Doria1 | 1Azienda ospedaliera universitaria di Padova, unità di Reumatologia, Padova, Italy
29 -
PO:16:231 | Differential clinical features of systemic lupus erythematosus patients on biological therapies: insights from a monocentric cohort Pietro Francesco Pilo, Elisa Bellis, Claudia Garulli, Claudio Cruciani, Marta Saracco, Claudia Lomater, Elena Marucco, Gloria Crepaldi, Valeria Data, Annamaria Iagnocco, Mariele Gatto. | Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Torino, Italy.
132 -
PO:10:155 | Etanercept-induced lupus in a patient with rheumatoid arthritis: diagnostic challenges and multidisciplinary therapeutic approach Camilla Riboldi1|2, Claudia Iannone1|2, Maria Gerosa1|2, Roberto Felice Caporali1|2 | 1ASST G. Pini-CTO, U.O.C. di Clinica Reumatologica, Milano; 2Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Italy
135 -
PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
194 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
146 -
PO:26:088 | Rheumatologic immune-related adverse events from immune checkpoint inhibitors: a monocentric retrospective study Giulio Fraticelli1|2, Nicola Farina1|2, Alessandro Tomelleri1|2, Marco Matucci Cerinic1|2, Corrado Campochiaro1|2, Lorenzo Dagna1|2. | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital, Milano, Italy; 2Inflammation, Fibrosis and Ageing Initiative INFLAGE, IRCCS San Raffaele Hospital, Milano, Italy.
129 -
PO:35:224 | Capturing What BVAS Misses: Patient-Reported Outcomes Reflect Disease Activity and Burden in EGPA Marta Codirenzi1, Federica Davanzo1, Luca Iorio1, Eleonora Fiorin1, Roberta Prevedello1, Roberto Padoan1, Andrea Doria1 | 1Unità di reumatologia, dipartimento di medicina DIMED,Università degli studi di Padova, Italy
11
1 - 15 of 15 items
